Neuronal PPP2R5C in plasma is a potential biomarker for early diagnosis of Alzheimer's disease - PubMed
9 hours ago
- #PPP2R5C
- #biomarker
- #Alzheimer’s disease
- Neuronal PPP2R5C in plasma is identified as a potential biomarker for early diagnosis of Alzheimer's disease (AD).
- The study isolates neuron-derived exosomes (NDEs) from plasma of familial AD (FAD), presymptomatic FAD (pre-FAD), and healthy controls, using label-free LC-MS/MS analysis.
- A specific peptide from PPP2R5C shows a progressive decrease from healthy controls to pre-FAD and FAD patients.
- The decline in PPP2R5C is validated in plasma NDEs and brain tissue from amnestic mild cognitive impairment (aMCI) and sporadic AD (SAD) patients.
- Two independent cohorts confirm the early and differential diagnostic value of plasma PPP2R5C.
- Immunohistochemistry reveals PPP2R5C reduction precedes Tau hyperphosphorylation in Tau Braak-staged brains.
- Mechanistically, PPP2R5C interacts with Tau, reducing Tau levels and phosphorylation via ULK1-dependent autophagolysosomal activation and PP2A regulation.
- The findings suggest plasma PPP2R5C could serve as an ideal biomarker for early AD diagnosis.